subject area of
- A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab Journal Articles
- A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice Journal Articles
- A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants Journal Articles
- A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS) Journal Articles
- A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection Journal Articles
- A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age Journal Articles
- A review of cost–effectiveness of palivizumab for respiratory syncytial virus Journal Articles
- Adherence and outcomes: a systematic review of palivizumab utilization Journal Articles
- Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab Journal Articles
- Are late preterm infants as susceptible to RSV infection as full term infants? Journal Articles
- CARESS: The Canadian Registry of Palivizumab Journal Articles
- Changing costs and the impact on RSV prophylaxis Journal Articles
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis Journal Articles
- Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015) Journal Articles
- Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants Journal Articles
- Current strategies in the prevention of respiratory syncytial virus disease Journal Articles
- Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory‐syncytial‐virus‐related infection in cystic fibrosis children less than 2 years of age? Journal Articles
- Expert consensus on palivizumab use for respiratory syncytial virus in developed countries Journal Articles
- Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia Journal Articles
- First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015) Journal Articles
- High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention Journal Articles
- Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab Journal Articles
- Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective Journal Articles
- Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants Journal Articles
- Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy Journal Articles
- Palivizumab Adherence and Outcomes in Canadian Aboriginal Children Journal Articles
- Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes Journal Articles
- Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Journal Articles
- Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017 Journal Articles
- Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab Journal Articles
- Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority Journal Articles
- Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations Journal Articles
- Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab Journal Articles
- Respiratory syncytial virus (RSV) infection in children with medical complexity Journal Articles
- Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes Journal Articles
- Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Journal Articles
- Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study Journal Articles
- Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016) Journal Articles
- Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders Journal Articles
- Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries Journal Articles
- Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention Journal Articles
- Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada Journal Articles
- Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data Journal Articles
- Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention Journal Articles
- The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation Journal Articles
- The Real‐Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut Journal Articles
- The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence Journal Articles
- The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic Journal Articles
- The cost effectiveness of palivizumab: a systematic review of the evidence Journal Articles
- The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis Journal Articles
- The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study Journal Articles
- Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada Journal Articles